Patents by Inventor Peter A. Crooks

Peter A. Crooks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180186756
    Abstract: The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Inventors: Nikhil Reddy Madadi, Narsimha Reddy Penthala, Peter Crooks, Leena Maddukuri, Robert Eoff
  • Patent number: 9981990
    Abstract: The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML). A compound comprising Formula (1) wherein: Z is independently selected from the group consisting of CH2, O, C(O), and CH, wherein when Z is CH, Z is connected to Y via a double bond and Y is N.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 29, 2018
    Assignees: BIOVENTURES, LLC, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Venumadhav Janganati, Peter Crooks, Narsimha Reddy Penthala, Craig Jordan, Shobanbabu Bommagani, Jessica Ponder
  • Publication number: 20180118710
    Abstract: The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 3, 2018
    Inventors: Narsimha Reddy Penthala, Peter Crooks, Vijayakumar Sonar
  • Patent number: 9938246
    Abstract: The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 10, 2018
    Assignee: BIOVENTURES, LLC
    Inventors: Nikhil Reddy Madadi, Narsimha Reddy Penthala, Peter Crooks, Leena Maddukuri, Robert Eoff
  • Patent number: 9920063
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, thiocarbamates, ester and amide derivatives of MMB. These derivatives are useful for treating cancer in humans.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: March 20, 2018
    Assignees: BIOVENTURES, LLC, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Shobanbabu Bommagani, Peter Crooks, Narsimha Reddy Penthala, Venumadhav Janganati, Craig T. Jordan, Jessica Ponder
  • Patent number: 9908892
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 6, 2018
    Assignee: BIOVENTURES, LLC
    Inventors: Venumadhav Janganati, Narsimha Reddy Penthala, Peter A. Crooks, Craig T. Jordan
  • Patent number: 9884842
    Abstract: The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: February 6, 2018
    Assignee: BIOVENTURES, LLC
    Inventors: Narsimha Reddy Penthala, Peter Crooks, Vijayakumar Sonar
  • Publication number: 20170362254
    Abstract: The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML). A compound comprising Formula (1) wherein: Z is independently selected from the group consisting of CH2, O, C(O), and CH, wherein when Z is CH, Z is connected to Y via a double bond and Y is N.
    Type: Application
    Filed: December 3, 2015
    Publication date: December 21, 2017
    Inventors: Venumadhav Janganati, Peter Crooks, Narsimha Reddy Penthala, Craig Jordan, Shobanbabu Bommagani, Jessica Ponder
  • Publication number: 20170226072
    Abstract: The present invention is directed to 1,4-disubstituted piperidines, 1,4-disubstituted piperazines, 1,4-disubstituted diazepanes, and 1,3-disubstituted pyrrolidine compounds and their use.
    Type: Application
    Filed: April 24, 2017
    Publication date: August 10, 2017
    Inventors: Peter A. CROOKS, Linda P. DWOSKIN, John CULVER, Justin R. NICKELL, Guangrong ZHENG
  • Publication number: 20170224698
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R3, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 me
    Type: Application
    Filed: September 19, 2016
    Publication date: August 10, 2017
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Patent number: 9649301
    Abstract: Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 16, 2017
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter Crooks, Linda Dwoskin, Guangrong Zheng, Sangeetha Sumithran, David Allen, Zhenfa Zhang, Paul Lockman
  • Patent number: 9597316
    Abstract: Provided herein are compounds, comprising Formula (I) or Formula (II), and their pharmaceutically acceptable salts. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one compound of Formula (I) and (II), singly or in combination with other pharmaceutically active ingredients, such as anti-inflammatory agents or anticancer agents. These compounds and pharmaceutical compositions are useful for treating inflammation or an inflammation related disorder in a subject via administration to the subject. These compounds and pharmaceutical compositions are also useful for inhibiting COX-2, for treating cancer, for reducing the size of a neoplasm, and for inhibiting tubulin polymerization in a cell.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 21, 2017
    Assignee: BIOVENTURES LLC
    Inventors: Narsimha Reddy Penthala, Peter Crooks
  • Patent number: 9550753
    Abstract: Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and gastrointestinal tract disorders.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: January 24, 2017
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran, Zhenfa Zhang
  • Publication number: 20170015635
    Abstract: The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: Nikhil Reddy Madadi, Narsimha Reddy Penthala, Peter Crooks, Leena Maddukuri, Robert Eoff
  • Patent number: 9540327
    Abstract: Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: January 10, 2017
    Assignee: University of Kentucky Research Foundation
    Inventors: Peter Crooks, Linda P. Dwoskin, Guangrong Zheng, Sangeetha Sumithran
  • Publication number: 20160368929
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Applicants: The Board of Trustees of the University of Arkansas, University of Rochester
    Inventors: Venumadhav Janganati, Narsimha Reddy Penthala, Peter A. Crooks, Craig T. Jordan
  • Publication number: 20160368928
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, thiocarbamates, ester and amide derivatives of MMB. These derivatives are useful for treating cancer in humans.
    Type: Application
    Filed: August 30, 2016
    Publication date: December 22, 2016
    Inventors: Shobanbabu Bommagani, Peter Crooks, Narsimha Reddy Penthala, Venumadhav Janganati, Craig T. Jordan, Jessica Ponder
  • Patent number: 9499518
    Abstract: Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: November 22, 2016
    Assignees: University of Kentucky Research Foundation, University of Utah
    Inventors: Joseph R. Holtman, Peter A. Crooks, Linda P. Dwoskin, J. Michael McIntosh, Elzbieta Pogonowska Wala
  • Patent number: 9487536
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, thiocarbamates, ester and amide derivatives of MMB. These derivatives are useful for treating cancer in humans.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 8, 2016
    Assignees: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Shobanbabu Bommagani, Peter Crooks, Narsimha Reddy Penthala, Venumadhav Janganati, Craig T. Jordan, Jessica Ponder
  • Patent number: 9469650
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: October 18, 2016
    Assignees: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, UNIVERSITY OF ROCHESTER
    Inventors: Venumadhav Janganati, Narsimha Reddy Penthala, Peter A. Crooks, Craig T. Jordan